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Abstract
Hemostasis  is  the process of  cessation of  blood loss.  Alterations of  the hemostatic
pathways  can  result  in  a  hypercoagulable  or  hypocoagulable  state  resulting  in
thrombosis or hemorrhage. Common defects in hemostasis and their management,
specifically the hypocoagulable state,  are discussed as these defects often result  in
increased perioperative blood loss, which can result in compromised patient outcomes.
Keywords: hemostasis, platelets, coagulation, bleeding, hemophilia, von Willebrand
disease, warfarin, Coumadin, heparin, fondaparinux, Arixtra, Aspirin, PGY12 block‐
ers, clopidogrel, ticagrelor, direct oral anticoagulants, dabigatran, Pradaxa, rivaroxa‐
ban, Xarelto, apixaban, Eliquis, thrombocytopenia, ITP, liver disease, kidney disease,
Surgicel, Gelfoam, topical thrombin, HemCon, CollaPlug, tranexamic acid, aminocap‐
roic acid
1. Introduction
The process of hemostasis can be divided into four phases namely formation of the plate‐
let plug, clot development via the coagulation cascade, termination of the coagulation
cascade, and clot fibrinolysis [1]. The formation of the platelet plug can be described as
primary hemostasis. Clot development via the coagulation cascade is subsequently termed
secondary hemostasis. Primary hemostasis occurs immediately following endothelial cell
damage and includes a vascular phase and a platelet phase. The vascular phase occurs
following vascular injury and results in the vasoconstriction of the blood vessel. The platelet
phase follows the vascular phase and consists of the formation of the initial platelet plug.
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The formation of the platelet plug includes activation, adhesion, and aggregation. Platelet
activation occurs via exposure of platelets to subendothelial collagen [2]. This results in a
conformational change of the platelets as well as a release of granules within the platelets.
This is followed by platelet adhesion to the subendothelial collagen in damaged blood
vessels via von Willebrand's factor (VWF) and GP1b [3]. Platelet activation and the produc‐
tion of platelet products including thromboxane A2, ADP, and serotonin result in a
conformational change in GPIIb/IIIa on platelets that allows platelets to bind to fibrinogen
resulting in platelet aggregation (Figure 1) [4].
Figure 1. Primary hemostasis.
Secondary hemostasis results in clot development via the coagulation cascade, in which
activation of serine protease zymogens results in the conversion of fibrinogen to fibrin and the
cross‐linking of fibrin that stabilizes the initial platelet plug. Traditionally, the coagulation
cascade is broken down into the extrinsic and intrinsic pathways. The extrinsic pathway is
initiated when tissue factor from damaged endothelial cells within the disrupted vasculature
binds to factor VII, leading to the activation of factor X and the common pathway of the
coagulation cascade. In the intrinsic pathway, activation of high molecular weight kininogen,
conversion of prekallikrein to kallikrein, and activation of factors XII, XI, IX, and VIII leads to
the activation of factor X and the common pathway of the coagulation cascade. The common
pathway includes the activation of factors X, V, thrombin, and the conversion of fibrinogen to
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fibrin by thrombin, resulting in the formation of the fibrin clot. Thrombin also upregulates
other upstream clotting factors including V, VIII, and XI, further promoting the formation of
thrombin and the fibrin clot via the extrinsic pathway [5]. Termination of the coagulation
cascade occurs via activation of antithrombin, tissue factor inhibitor, thrombomodulin, protein
C, and protein S [6, 7]. In the fibrinolytic phase, plasminogen is converted to plasmin via tissue
plasminogen activator. The effect of plasmin is to cleave fibrin and fibrinogen leading to the
dissolution of the clot (Figures 2 and 3) [8].
Figure 2. Extrinsic/intrinsic pathways. Termination of coagulation cascade.
Figure 3. Fibrinolysis.
This chapter deals with the management of inherited, acquired, and iatrogenically induced
coagulopathies in oral surgery.
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2. Inherited and Acquired Coagulopathies
2.1. Overview
As hemostasis occurs via primary and secondary mechanisms, coagulopathies can be divided
into similar categories. Defects in primary and secondary hemostasis typically have different
presentations. Characteristically, primary hemostatic disorders, or defects in platelet function,
result in mucocutaneous bleeding such as epistaxis, petechiae, menorrhagia, and ecchymosis
[9]. Secondary hemostatic disorders, or defects in the coagulation cascade, result in deep
bleeding such as hematomas and hemarthroses. Disorders of hemostasis can also be divided
into congenital and acquired disorders of hemostasis. Acquired disorders are the most
common cause of prolonged bleeding. In contrast to the congenital disorders in which only
one factor is typically affected, the acquired coagulation disorders often have multiple factors
affected. Congenital disorders of primary hemostasis include platelet function disorders
(PFDs) and von Willebrand disease (VWD). Congenital disorders of secondary hemostasis
include hemophilias A and B. Acquired disorders of hemostasis include immune thrombocy‐
topenia (ITP), uremia‐induced platelet dysfunction, defects due to chronic liver failure, and
iatrogenic or medication‐induced coagulopathies (Tables 1 and 2).
Minor
surgery
Major
surgery
Mild
renal impairment
Moderate
renal impairment
Pre‐op Post‐op Pre‐op Post‐op
Warfarin INR <3.0 Adequate
hemostasis/
next
morning
Hold 5 days Adequate
hemostasis/
next
morning
Heparins
Heparin 4–6 h Once
hemostasis
achieved
4–6 h 48–72 h
LMWH 24 h 24 h 24 h 48–72 h
Fondaparinux 48 h 24 h 96 h 24 h 72–120 h 72–144 h
Platelet
inhibitors
Aspirin None None None None
Clopidogrel None None None None
Dual
‐antiplatelet
therapy
None None None None
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Minor
surgery
Major
surgery
Mild
renal impairment
Moderate
renal impairment
Pre‐op Post‐op Pre‐op Post‐op
Direct
anticoagulants
Dabigatran 48 h, PT
or PTT
compared
to normal
<1.2X
24 h 72 h, PT
or PTT
compared
to normal
<1.2X
48–72 h 48–72 h 72–120 h
Rivaroxaban 48 h, PT:PTT
<1.2×
24 h 72 h, PT:PTT
<1.2×
48–72 h 48–72 h 72–96 h
Apixaban 48 h 24 h 72 h 48–72 h 48–72 h 72–96 h
*Determination to bridge based on risk for thromboembolism in consultation with cardiologist.
**In patients with low risk for cardiovascular event aspirin may be discontinued 7–10 days prior to surgery.
***There are no RCTs evaluating bleeding risk with dental extractions.
Table 1. Perioperative management of antithrombotic therapy.
Hemostatic agent Description Features
Gelfoam Gelatin sponge Highly absorptive
Matrix for coagulation cascade
Neutral pH can be used in combination with topical thrombin
Surgicel Oxidized regenerated
cellulose
Bactericidal
Acidic pH should not be used with topical thrombin
Reported negative effect on nerve function
CollaCote,
CollaTape,
CollaPlug
Collagen product Highly absorptive
Matrix for coagulation cascade
Topical thrombin Converts fibrinogen to
fibrin
Converts fibrinogen to fibrin in final step of coagulation cascade
Gelfoam can be soaked in liquid thrombin for increased hemostasis
Tranexamic acid Inhibits conversion of
plasminogen to plasmin
Gauze soaked in 5% tranexamic acid liquid for hemostasis
Liquid 4.8% tranexamic acid q6h 2–5 days as postoperative mouth rinse
for hemostasis
HemCon Chitosan agent Antimicrobial properties
Sutures not required for placement
See Refs. [100, 164].
Table 2. Local hemostatic agents.
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2.2. Inherited disorders of hemostasis
2.2.1. Platelet function disorders (PFDs)
Platelets are anucleate cellular fragments derived from megakaryocytes. Platelets are pro‐
duced via the activation of the hormone thrombopoietin (TPO), have an average life span of
7–10 days, and are critical to primary hemostasis. The normal blood cell count of platelets is
150,000–450,000/μl [10]. When endothelial injury occurs, von Willebrand's factor is able to via
bind to subendothelial collagen. Platelets then bind to von Willebrand's factor, the platelet
GP1b glycoprotein. Platelet activation via exposed collagen and other platelet agonists is
followed by aggregation via GPIIb/IIIa. Platelet activation leads to the secretion of thrombox‐
ane and the secretion of ADP and serotonin from the dense granules. This further promotes
platelet activation and aggregation that propagates primary hemostasis [2–4, 9].
Historically, von Willebrand disease has been identified as the most common inherited defect
of primary hemostasis, but recent studies suggest that platelet function disorders (PFDs) may
actually be more common [11]. Individuals with PFDs commonly have symptoms of abnor‐
malities in primary hemostasis including mucocutaneous bleeding, ecchymosis, menorrhagia,
and epistaxis [9]. Severe forms of PFDs are rare and include Bernard‐Soulier syndrome, a
deficiency in GP1b, and Glanzmann thrombasthenia, a deficiency in GPIIb/IIIa. Less severe
forms of platelet function disorder are more common and may include defects in receptors,
platelet agonists, platelet storage granule defects, and signal transduction defects [9].
Traditionally, bleeding time was used to evaluate platelet function, but this has fallen out of
favor. The platelet function screen (PFS) is used more often today and is readily available at
most hospitals. The downside of the PFS is its low sensitivity, especially in cases of mild platelet
function defect [12]. The best test for diagnosis of platelet function disorders is light transmis‐
sion aggregometry (LTA), in which platelet aggregation is promoted via agonists leading to
an increase in light transmission that can be quantified [12]. However, LTA is not readily
available and is thus rarely utilized in clinical testing. Due to the limitations of clinical
diagnostic testing as noted above, patients with symptoms of mucocutaneous bleeding
without laboratory abnormalities may not be diagnosed. These patients can be identified as
having mucocutaneous bleeding of unknown cause [9]. In patients with platelet function
disorders, the use of local measures and antifibrinolytics, such as a 5% tranexamic acid
mouthwash every 4–6 h perioperatively, should be a mainstay of therapy for patients under‐
going oral surgery procedures. If moderate bleeding is expected, desmopressin at a dose of
0.3 μg/kg (max dose 20 μg) can be administered intravenously 1 h prior to procedure [13]. In
patients with severe risk of bleeding or severe forms of PFDs, such as Bernard‐Soulier
syndrome or Glanzmann thrombasthenia, perioperative platelet transfusion may be indicated.
Platelet transfusions are rarely used for patients with mild forms of PFDs [13]. Some risks
associated with platelet transfusions include the development of HLA antibodies or antibodies
to platelet glycoproteins. Additional risks of blood components include the transmission of
infectious diseases, which is discussed.
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2.1.2. Von Willebrand disease
Von Willebrand disease (VWD) has been historically identified as the most common inherited
bleeding disorder. VWD is caused by an inherited defect in the concentration, structure, or
function of von Willebrand's factor [14]. VWD can be the result of a qualitative or quantitative
defect in VWF. The prevalence of all types of VWD is estimated to be around 1 in 100 [15].
VWF is synthesized in vascular endothelial cells and megakaryocytes. Within the endothelial
cells, VWF can be stored in Weibel‐Palade bodies or released directly from the endothelial
cells. In platelets, VWF is stored in the alpha‐granules [16]. VWF plays a role in both primary
and secondary hemostasis, and therefore, VWD may include symptoms of defects in both
primary and secondary hemostasis. In primary hemostasis, VWF promotes subendothelium
binding to platelets via GP1b. VWF further promotes binding between platelets via GPIIb.
During secondary hemostasis, VWF stabilizes Factor VIII, promoting the coagulation cascade
[17].
Type I VWD is the most common form of VWD, accounting for 60–80% of all cases. It is defined
by 10–45% of circulating levels of VWF. Type I VWD is also inherited in an autosomal‐
dominant fashion, but is usually found incidentally during a surgical procedure.
Type II VWD is usually an inherited autosomal‐dominant disorder and is considered a
qualitative disorder. Subtypes of Type II VWD include IIA, IIB, IIM, and IIN. Type IIA VWD
is due to a defect in the synthesis of high and medium molecular weight VWF multimers or
an increase cleavage of VWF by ADAMS13 [17]. Type IIB VWD is caused by a gain‐of‐function
mutation in the GPIb binding site of VWF. This results in activation of VWF and platelet
aggregation, followed by clearance of VWF and platelets. Patients with Type IIB VWD may
present with thrombocytopenia [17]. Type IIM is due to a decrease in interaction between VWF
and platelets [17]. Type IIN is inherited in an autosomal recessive manner and is due to a
mutation in the factor VIII binding site of VWF [17].
Type III VWD is inherited in an autosomal recessive manner and is considered the most severe
form of VWD, as no VWF is produced [15]. There is great inter‐individual variability between
the different types and subtypes of VWD, resulting in variable risks of hemorrhage from minor
to severe. Therefore, hemorrhage risk should be evaluated on a case‐by‐case basis.
VWD is diagnosed via the qualitative ristocetin cofactor assay (VWF:RCo) and the quantitative
measurement of the amount of circulating von Willebrand's factor antigen (VWF:Ag) [18].
Type I and Type II VWD can be differentiated based on differences in ratios between the two
assays, where a decrease in the VWF:RCo/VWF:Ag <0.6 is indicative of Type II VWD and a
ratio VWF:RCo/VWF:Ag >0.6 is indicative of Type I VWD [17]. The PTT and bleeding time are
often elevated in patients with VWD [19]. Management of Type I VWD includes the use of
desmopressin, which results in a release of stored VWF. Due to inter‐individual variability in
response to desmopressin treatment, in patients with Type I VWD, a preliminary test dose to
verify biological response to desmopressin is recommended [17]. Desmopressin is effective in
most cases of Type I VWD, but is not used in Type II VWD or Type III VWD [20]. Type II VWD
may actually be aggravated by the use of desmopressin. Specifically, in Type IIB VWD, there
is a risk for the aggravation of thrombocytopenia [21]. The peak response to desmopressin
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infusion occurs between 90 min and 2 h post‐infusion, and therefore, surgery is recommended
within 2 h post‐infusion. Bornert et al. used a protocol of IV infusion (50 ml/30 min) of 0.2 μg/
kg 1 h preoperatively, 10 h postoperatively, and 24 h postoperatively to obtain hemostasis in
a pediatric patient with Type I VWD undergoing dental extractions [22]. This protocol can be
used as a basic guideline for treatment of patients with Type I VWD undergoing dental
extractions; alternatively, the use of 300 μg intranasal preoperatively in patients >50 kg, 150 
μg intranasal in patients <50 kg, or subcutaneous 0.3 μg/kg max dose of 15 μg may also be
considered [23–25]. The use of local hemostatic measures and antifibrinolytics is also recom‐
mended in the treatment of VWD. In cases of severe VWD, VWF/FVIII infusions have been
used [17].
2.1.3. Hemophilias A and B
Hemophilias A and B are X‐linked recessive bleeding disorders. Patients with hemophilia are
unable to activate Factor X and therefore are unable to generate thrombin and fibrin necessary
to stabilize the initial platelet plug. Hemophilia A is caused by a defect in Factor VIII and
Hemophilia B, also known as Christmas disease, is caused by a defect in Factor IX. The
incidence of Hemophilia A is approximately 1 in 5000, and the incidence of Hemophilia B is 1
in 30,000 [26]. Males are generally affected, whereas female carriers are generally asympto‐
matic, with some female carriers having symptoms similar‐to‐mild hemophilia [27]. While
most cases of hemophilia have a family history of the bleeding disorder, approximately one‐
third of the cases arise spontaneously, with hemophilia occurring due to a de novo maternal
mutation [28]. Hemophilias A and B can be further categorized based on the concentration of
functional Factor VIII or IX. Severe hemophilia is identified as less than 1% of normal factor
activity, moderate hemophilia 1–5% of normal factor activity, and mild hemophilia as 5–40%
of normal factor activity [29, 30]. Two‐thirds of patients with Hemophilia A have severe
hemophilia, and one‐half of patients with Hemophilia B have severe hemophilia. The average
age of diagnosis of hemophilia for severe hemophilia is at 1 month of age, 8 months for
moderate hemophilia, and 3 years for mild hemophilia. A family history of hemophilia or of
mother carrier status increases the likelihood of diagnosis [31]. In mild hemophilia, the
diagnosis may be challenging as diagnosis may only be made after a bleeding episode during
surgery or trauma [32]. Symptoms in newborns include bleeding after circumcision and
intracranial hemorrhage [33, 34]. Symptoms that present during early childhood include
bruising, joint bleeds, and “goose‐egg” hematomas of the forehead [35]. Symptoms that
present later in childhood or during adult life include hemarthrosis and hematomas. Joints
with frequent hemarthrosis are likely to develop arthropathy during adolescence [36]. In
trauma patients with a history of hemophilia, there is an increased risk for life‐threatening
intracranial hemorrhage, which can present clinically as headache, vomiting, seizures, and
lethargy [37]. In those patients with a family history of Hemophilia A, diagnosis can be made
at birth by measuring Factor VIII levels on the umbilical cord blood [17]. In patients with a
family history of Hemophilia B, diagnosis can be made between 6 and 12 months, as at birth
Factor IX levels are low in all individuals [26]. Laboratory results in hemophilia indicate a
prolonged PTT with normal PT and INR. A normal PTT does not exclude hemophilia due to
a low sensitivity of the screening test. A prolonged PTT is then confirmed by identifying
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decreased functional Factor VIII or IX at less than 40% of normal [17]. In patients with suspected
Hemophilia A, a normal VWF:Ag should be present to rule out decreased Factor VIII as a result
of von Willebrand Disease.
Once a diagnosis of hemophilia is made, patients should be vaccinated against Hepatitis B. At
one year of age, vaccination against Hepatitis A can be administered to prevent viral trans‐
mission during the transfusion of blood products [38]. Management of hemophilia with acute
bleeding can be achieved with factor replacement, fresh‐frozen plasma (FFP), local measures,
antifibrinolytic agents, and desmopressin in patients with Hemophilia A. Today, factor
replacement is preferred to FFP due to relative concentrations of the products and decreased
risk of transmission of blood borne pathogens. Long‐term management of patients with
hemophilia includes prophylactic treatment with factor replacement. Prophylaxis is achieved
by maintaining the missing clotting factor at a level of 1% or higher. These protocols have
resulted in a decrease in the chronic morbidities associated with hemophilia, such as arthrop‐
athy [39]. For factor replacement, one unit of Factor VIII per kg of body weight increases the
plasma FVIII level by 2%. For Factor IX replacement, one unit of Factor IX per kg of body
weight increases the plasma IX level by 1%. The half‐life of Factor VIII is 8–12 h so twice‐daily
dosing is required. The half‐life of Factor IX is 24 h so dosing is limited to once daily [40–42].
The control of serious bleeding is usually achieved by maintaining factors levels at 50–100%
for a period of 7–10 days [43, 44]. Prophylaxis to prevent serious bleeding complications in
patients with hemophilia includes achieving 100% factor function for a period of 1 week prior
to surgery. Factor replacement is typically maintained postoperatively for 1–3 days [39].
Desmopressin can also be used in the management of Hemophilia A. Desmopressin at 0.3 μg/
kg body weight is expected to raise FVIII levels by twofold within an hour post‐infusion. This
can be repeated after 12 h and once daily thereafter [45, 46]. Intranasal administration of 300 
μg of desmopressin preoperatively in patients >50 kg, 150 μg intranasal in patients <50 kg, or
subcutaneous 0.3 μg/kg max dose of 15 μg may also be considered [23–25]. Desmopressin is
dependent on existing Factor VIII as it promotes the release of VWF, allowing for stabilization
of Factor VIII. Therefore, desmopressin is ineffective in severe hemophilia (<1% activity) and
in treating Hemophilia B [17].
Factor replacement therapy has its potential complications, such as the development of
antibodies against the replaced factors. The development of inhibitors is reported to develop
in 20% of severe cases of Hemophilia A and 3–5% of patients with Hemophilia B [47]. The
development of inhibitor antibodies is diagnosed via mixing studies where the addition of the
missing protein to the plasma of a subject with an inhibitor does not correct an abnormal PTT.
The Bethesda assay is used to qualify patients with inhibitors into low responders or high
responders. Low responders are patients with BU <5 and respond well to high doses of factor
replacement. High responders, or patients with BU >10, do not respond well to factor replace‐
ment and are treated with concentrates of other factors including Factor VII to promote the
intrinsic pathway of the coagulation cascade [48]. The future of hemophilia treatment likely
includes the development of long‐acting factor replacements and gene therapy [49]. In patients
born before 1985, the leading cause of death in patients with hemophilia is complications from
HIV or Hepatitis C due to contamination of the plasma supply [50, 51]. Today, the preferred
Management of Inherited, Acquired, and Iatrogenically Induced Coagulopathies in Oral Surgery
http://dx.doi.org/10.5772/63724
183
use of recombinant factors and improved methods in removing viruses from the donor blood
supply has decreased the viral rate of transmission. Complications related to liver failure as a
result of Hepatitis C further increases difficulties in managing the coagulopathy in these
patients.
2.1.4. Hemophilia C
Factor XI deficiency or Hemophilia C is the fourth most common inherited bleeding disorder
after VWD, Hemophilia A, and Hemophilia B. Hemophilia C is most common in the Ashkenazi
Jewish population with 8% of this population being heterozygous [52, 53]. Unlike Hemophilias
A and B, Factor XI deficiency is not defined by spontaneous bleeding into muscles and joints
[52]. Hemophilia C can also be seen in both sexes, whereas Hemophilias A and B are inherited
in an X‐linked recessive manner and therefore are more common in males. Hemophilia C was
first identified in two sisters, one of which had a tonsillectomy and the other a dental extraction
[54]. Factor XI deficiency is most commonly identified after trauma or surgery to tissues with
high fibrinolytic properties including the oral mucosa. Bleeding occurs more commonly in
tissues with high fibrinolytic properties because the normal function of Factor XI is to stabilize
thrombin‐activated fibrinolysis inhibitor (TAFI), an inhibitor of fibrinolysis [55]. An elevated
PTT is seen in patients with Hemophilia C with confirmation of Hemophilia C via measure‐
ment of Factor XI levels. Patients with <20 μ/dl are identified as having a severe deficiency of
Factor XI and patients with a Factor XI level of 20–80 μ/dl as having a partial deficiency [56].
The degree of Factor XI deficiency is poorly correlated with bleeding tendency for patients
with partial deficiency. Overall, a history of bleeding episodes is more significant than the
specific level of Factor XI [53]. In patients undergoing dental extractions, the use of tranexamic
acid is an effective treatment. Berliner et al. reported no episodes of prolonged bleeding in
patients with severe Factor XI deficiency <15 μ/dl when tranexamic acid was used 12 h prior
to procedure and continued for 7 days post‐extraction [57]. In surgeries where more severe
bleeding is expected the use of fresh‐frozen plasma (FFP), 15 ml/kg within two days prior to
surgery is an effective treatment modality [53]. Prior to transfusion with FFP, patients should
be tested for Factor XI inhibitors [58]. If inhibitors are present, alternative treatment modalities
should be explored including Factor VIIa. A single dose of Factor VIIa (15–30 μl/kg) in
combination with tranexamic acid perioperatively has been effective in obtaining hemostasis
in patients with Factor XI inhibitors [58]. Patients with severe Factor XI deficiency should be
transfused with FFP to Factor XI levels of 30–40 μ/dl, which can be identified via Factor XI
testing or a normalized PTT [53]. Factor XI should not be normalized due to increased risk of
thrombosis. Risks of FFP include fluid overload and those risks associated with blood
products. Factor XI concentrate is another effective treatment modality, but due to the risk of
thrombosis formation, Factor XI concentrate is not currently available in the United States [53].
2.1.5. Other inherited coagulopathies
Other rare forms of inherited coagulation disorders make up 3–5% of all coagulation disorders.
These include deficiencies in fibrinogen, prothrombin, factor V, Factor V and VIII, VII, X, and
XIII deficiency [17, 59–61]. These disorders can be screened for using PT, PTT, and INR assays.
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If positive results are present, then a secondary diagnostic assay of factor activity can be
performed [17]. Unique to the rare forms of inherited coagulopathies a normal PT, PTT, and
INR with symptoms of CNS bleeding or hemarthrosis may indicate a Factor XIII deficiency
[17, 62]. Treatment for these coagulopathies usually includes factor replacement [60].
2.3. Acquired disorders of hemostasis
2.3.1. Thrombocytopenia
There are various causes of thrombocytopenia including decreased platelet production,
increased destruction, sequestration, dilution and consumption within clots. Some causes of
thrombocytopenia are associated with hemorrhage, while others are associated with increased
risk of thrombosis. Thrombocytopenia associated with increased risk of thrombosis includes
heparin‐induced thrombocytopenia (HIT), disseminated intravascular coagulation (DIC),
thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and drug‐
induced thrombotic microangiopathy. Thrombocytopenia occurs in these disorders as
platelets are consumed during the formation of clots. Thrombocytopenia in the presence of
pancytopenia is indicative of a defect in the bone marrow including nutritional deficiencies,
myelodysplastic syndromes, and acute leukemia. Additionally, drugs used to treat malignan‐
cies may cause pancytopenia. Isolated thrombocytopenia may be indicative of congenital
thrombocytopenia, thrombocytopenia during pregnancy, autoimmune diseases, immune
thrombocytopenia (ITP), drug‐induced thrombocytopenia, or liver disease [63]. Patients who
present with thrombocytopenia with a recent change in medications should be evaluated for
drug‐induced thrombocytopenia. The mechanism of thrombocytopenia in patients with liver
disease is via spleen sequestration of platelets secondary to splenomegaly due to portal
hypertension. Thrombocytopenia can be associated with infections viral, bacterial, or parasitic.
Thrombocytopenia has been reported to be an initial presentation of HIV [64]. Patients with
unexplained thrombocytopenia have a complex differential diagnosis and should be referred
to a hematologist for consultation and complete workup. The average platelet count is 150,000–
450,000/μl representing great variability between individuals. While there is greater variability
in platelet count between individuals, individuals typically have a consistent platelet level [65].
Therefore, a change in platelet count may be more indicative of an increased risk of hemorrhage
compared to the platelet value itself. A platelet value below 150,000/μl is defined as thrombo‐
cytopenia with severe thrombocytopenia being defined as a platelet count below 50,000/μl.
Severe thrombocytopenia may pose a risk for hemorrhage during surgical procedures, while
spontaneous bleeding does not typically occur unless the platelet count is less than 10,000/μl.
Bleeding time should be evaluated in patients with thrombocytopenia. The bleeding time can
be estimated by bleeding time = 30.5 (platelet count/3850) [66]. Patients with thrombocytopenia
should be transfused to a platelet count of 50,000/μl prior to minor procedures and 100,000/μl
for more invasive procedures [66]. Patients should be transfused with platelets the morning
of surgery due to the high rate of platelet consumption or sequestration. A platelet count
should be taken post‐transfusion. A history of prior transfusions is important to identify due
to increased alloimmunization of the recipient against platelet products. Additional transfu‐
sions intraoperatively or postoperatively may be necessary. In addition to platelet transfusions,
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local hemostatic measures including gelatin sponge, oxidized regenerated cellulose, topical
thrombin, aminocaproic acid, and tranexamic acid should be used to obtain and maintain
hemostasis. In patients undergoing dental extractions with a platelet count of <100,000/μl and
when <50,000/μl were transfused with platelets, Fillmore et al. reported a 7.4% risk of postop‐
erative bleeding, all of which were controlled via local measures [67].
2.3.2. Immune Thrombocytopenia
Immune thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenic purpura,
is an immune‐mediated thrombocytopenia in children, adults, or during pregnancy. ITP is a
disease of exclusion with a differential diagnosis including thrombotic thrombocytopenic
purpura (TTP), chronic liver disease, aplastic anemia, leukemia, Type IIB von Willebrand
disease, drug‐induced thrombocytopenia, myeloproliferative disorders, and HIV [68]. The
presentation of ITP in children and adults differs, as in children ITP typically occurs after a
viral infection and typically resolves spontaneously. ITP in adults is typically a chronic disease.
ITP in adults is identified as either primary ITP or secondary ITP.
Primary ITP occurs suddenly with no apparent precipitating event. Secondary ITP occurs in
patients with other morbidities including HIV, Hepatitis C, malignancies, or other autoim‐
mune diseases. The cause of ITP is the production of IgG autoantibodies to platelet proteins,
notably GPIIb/IIIa [69]. Once opsonized, platelets are destroyed by the reticuloendothelial
system [68]. Clinical manifestations of ITP include bleeding consistent with a platelet defect.
Symptoms include petechiae, purpura, epistaxis, and most severely intracranial hemorrhage.
Intraoral blisters or bleeding known as “wet purpura” has historically been identified as a
more concerning presentation than petechiae or purpura of the skin [70]. Typically, sponta‐
neous bleeding does not occur in patients with platelet counts greater than 30,000/ml, and
patients with a platelet count greater than 30,000/ml have mortality risks equal to the general
population [71, 72]. Patients with ITP typically have less bleeding risk than would be antici‐
pated by the reduced platelet count. This is likely related to the majority of platelets being
younger with greater hemostatic activity, as the autoimmune nature of ITP results in a
shortened platelet life span [73, 74]. Patients do not need to be treated for ITP unless platelet
counts are <10,000/ml, there is the presence of spontaneous bleeding, patients are scheduled
for surgery, or patients have lifestyles or occupational demands that increase the risk for
trauma [73]. The presence of comorbidities including chronic liver disease, hypertension,
infection, and uremia‐induced platelet dysfunction is another factor that should be considered
when deciding to treat patients with ITP [73]. Recommendations for safe practice in patients
undergoing surgical procedures are platelet count >30,000/ml for a single simple extraction,
>50,000/ml for minor surgery, and >80,000/ml for major surgery [68]. Typical first‐line therapy
in consultation with a hematologist includes prednisolone at 1 mg/kg for 2–4 weeks, followed
by tapering over several weeks. If corticosteroids are unsuccessful or not indicated, IVIG 1 
g/kg for 2 days or anti‐D 50 μg/kg once can be used. For patients who fail first‐line therapy,
second‐line therapy includes splenectomy, followed by additional pharmacotherapy [73]. In
the patient with ITP necessitating emergency surgery, a protocol including IVIG and platelet
transfusions is used [73–76].
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2.3.3. Liver disease
Common causes of chronic liver disease include viral hepatitis and alcoholic liver disease.
Candidates for liver transplantation due to liver cirrhosis are required to have dental clearance
as part of a preoperative evaluation prior to being placed on the transplant list. This often
includes extraction of carious dentition that is deemed to be an infection risk. The liver plays
a crucial role in hemostasis as the liver is the site of synthesis of thrombopoietin, most of the
coagulation factors, the inhibitors of the coagulation cascade and fibrinolytic proteins. In
addition to the site of synthesis, the liver is the site of metabolism of these factors. Due to
diminished procoagulant and anticoagulant factors, there is a rebalancing of hemostasis, and
most patients with liver disease undergoing surgical procedures do not exhibit excessive
bleeding [77]. Additionally, von Willebrand's factor (VWF) is not produced in the liver and is
elevated in patients with chronic liver disease. Increased VWF may contribute to maintenance
of primary hemostasis [78]. Patients with liver disease should be treated with caution, as the
balance between procoagulant and anticoagulant factors can easily be disrupted resulting in
either a hypercoagulable or hypocoagulable state. PT, INR, and PTT are commonly prolonged
in patients with liver failure, but this does not necessarily indicate an increased bleeding risk
as PT and PTT are unable to account for the decreased production of the anticoagulant factors
protein C, S, and antithrombin [77]. Prophylactic correction of prolonged PT with fresh‐frozen
plasma is not recommended prior to procedures due to limited reduction in bleeding risk and
the risks of blood products [79]. Additionally, volume overloading can increase the possibility
of varices rupturing as a consequence of portal hypertension [80]. Patients with liver disease
commonly present with moderate thrombocytopenia (50,000–100,000/μl) due to a decreased
production of thrombopoietin in the liver, as well as platelet sequestration in the spleen due
to portal hypertension [81]. For platelet count >50,000/μl, there is limited risk for significant
bleeding. For patients with a platelet count <50,000/μl, platelets should be transfused to
>50,000/μl. The use of antifibrinolytic agents such as tranexamic acid oral rinse preoperatively
is indicated to prevent bleeding complications. Stanca et al. successfully used intranasal
desmopressin (300 μg) in patients with INR of 2–3 and platelet count <50,000/μl prior to dental
extractions to promote hemostasis [82]. Additionally, platelet and coagulation factor deficien‐
cies may occur in alcoholics due to nutritional deficiencies in folic acid and vitamin K associ‐
ated with poor diets. Correction of folic acid and vitamin K (10 mg orally for 3 days) prior to
surgical intervention may be indicated. For pain management, NSAIDs should be avoided in
patients with liver disease due increased bleeding risk. Comorbidities that may increase
bleeding risk including current infection, uremia that impairs degranulation of platelets, and
medications that may affect coagulation. Infections should be treated and renal status opti‐
mized prior to surgical intervention [77]. As liver disease does not prevent against thrombosis,
prior to surgery, anticoagulant therapy should not be suspended solely based on liver disease
status [83].
2.3.4. Renal Dysfunction
In patients with renal dysfunction, there is an increased susceptibility to bleeding. This
increased bleeding risk is multifactorial and includes platelet dysfunction due to uremia,
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platelet dysfunction due to anemia, and the anticoagulant effects of heparin used during
dialysis. Platelet dysfunction due to uremia can affect all stages of platelet function including
adhesion, secretion, and aggregation [84]. This includes an increase in prostacyclin and nitric
oxide levels, decreased production of thromboxane A2, abnormal intracellular calcium
mobilization, and decreased production of ADP, epinephrine, and serotonin [85–88]. Well‐
characterized effects of uremia on platelet function include intrinsic platelet dysfunction in
GPIIb/IIIa resulting in decreased platelet aggregation and adhesion [89]. Uremia can also
induce platelet dysfunction extrinsic to platelets via the production of inhibitors including
guanidinosuccinic acid that increase nitric oxide levels [90]. Nitric oxide is a potent inhibitor
of platelet aggregation.
Anemia occurs in patients with renal dysfunction due to a decrease in erythropoietin. In a
patient with a normal hematocrit, red blood cells occupy the center of the blood vessel, while
the platelets are located at the periphery of the blood vessel. The peripheral location of platelets
in the blood vessel allows platelets to easily contact the subendothelial collagen when the
endothelium is damaged. In patients with anemia, the platelets are mixed with the red blood
cells and are less able to contact damaged endothelium [84].
Nishide et al. published a case report of increased hemorrhage in a patient with renal dys‐
function undergoing full mouth dental extractions and removal of hyperplastic gingiva two
months prior to kidney transplantation [91]. The authors noted no abnormalities in PT, PTT,
or bleeding time on preoperative laboratory tests. Abnormal laboratory results included
decreased hemoglobin of 7.2 g/dl and an elevated creatinine of 8.9 mg/dl consistent with renal
failure. In patients undergoing dialysis treatment, it is recommended that patients undergo
surgical procedures the day after dialysis when the anticoagulant effects of heparin have
subsided. To limit the negative effects of anemia on hemostasis, it is recommended to transfuse
patients to a hemoglobin of 10 g/dl preoperatively [92]. Additional strategies to promote
hemostasis preoperatively include the use of desmopressin single dose IV 0.3 μg/kg or 300 μg
intranasally 2 h prior to procedure [93]. The use of desmopressin increases the release of vWF,
therefore increasing the binding of platelets to subendothelial collagen in the damaged
endothelium. Estrogen 0.6 mg/kg IV or 2.5–25 mg orally beginning 5 days preoperatively can
also be used [94]. Estrogen promotes platelet function by limiting the production of nitric oxide
[95]. Additionally, the use of local hemostatic measures is recommended. Patients with chronic
renal failure may be at an increased risk of bleeding due to the presence of comorbidities such
as cardiovascular disease that are managed with antiplatelet therapy or vitamin K antagonists
[96, 97]. Patients with uremia should avoid NSAIDs as analgesics, as there is an increased risk
of bleeding.
3. Iatrogenically induced coagulopathies
3.1. Vitamin K antagonists (Warfarin)
Warfarin is a commonly used anticoagulant in patients with atrial fibrillation, history of
pulmonary embolism, possibility of deep vein thrombosis, and in patients with prosthetic
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heart valves. Warfarin management can be challenging based on the narrow therapeutic range
and other variables, such as drug interactions, diet, and systemic illnesses. Warfarin functions
by inhibiting the enzyme epoxide reductase, which reduces vitamin K from its oxidized form
so that it may participate in the carboxylation and activation of glutamate residues on
coagulation factors II, VII, IX, X, protein C, and protein S.
Protein C and protein S are endogenous anticoagulant proteins and have shorter half‐lives
than factors II, VII, IX, and X [98]. Therefore, the initial effect of warfarin is a hypercoagulable
state, with the anticoagulant effects of warfarin occurring after 2–3 days [99]. Due to the initial
hypercoagulable state, patients at a high risk for a thromboembolic event may undergo
bridging therapy with heparin for a period of 5–7 days. The effects of warfarin can be evaluated
via PT or INR testing. Warfarin has an oral bioavailability of 100%, and over 99% of warfarin
is bound to albumin. Due to the high protein binding of warfarin, the presence of other highly
protein bound drugs may lead to the displacement of protein bound warfarin resulting in an
increase in anticoagulation. Medications that promote the effects of warfarin include broad‐
spectrum antibiotics, fluconazole, metronidazole, erythromycin, cimetidine, phenytoin, and
propranolol [98]. Additionally, broad‐spectrum antibiotics may disrupt the normal gut flora,
resulting in a decrease in vitamin K absorption and an increase in the effect of warfarin [100].
Medications that antagonize the effects of warfarin include steroids, cholestyramine, griseo‐
fulvin, rifampin, barbiturates, and carbamazepine [98]. There is also great inter‐individual
variation in dose to achieve therapeutic anticoagulation due to genetic variation in the
cytochrome p450 enzymes, further necessitating the need for regular INR monitoring. Despite
genetic variation in p450 enzymes, genetic testing prior to initiation of warfarin therapy is not
recommended, as there is limited evidence to support reduced risk of bleeding or throm‐
boembolism with altered initial dosage; 5.0 mg once per day is the standard initial dosage for
patients initiating warfarin, as higher dosages have been associated with increased bleeding
events [101, 102]. In elderly patients or patients at increased sensitivity to warfarin, a lower
initial dose of 2.5 mg per day may be indicated [103]. In patients with thrombotic disease, the
INR is usually titrated to 2.0–3.0 and in patients with valvular disease it is titrated from 2.5 to
3.5.
Due to balancing the risk of hemorrhage while on warfarin and the increased risk for throm‐
boembolism in patients whose anticoagulation is discontinued, Ward and Smith determined
there remains a disparity in perioperative management of patients on warfarin undergoing
dentoalveolar procedures [104]. In most clinical situation, the trend is to limit modifications
to warfarin therapy and promote hemostasis with use of local hemostatic agents. In a random‐
ized controlled trial comparing maintenance of warfarin therapy to bridging with low
molecular weight heparin (LMWH), Bajkin et al. determined there was no statistical difference
in post‐extraction bleeding between the two groups when local hemostatic measures were
used. The authors concluded that in patients on warfarin with an INR of less than or equal to
4, simple dental extractions could safely be performed without modification to the patient's
oral anticoagulant therapy [105]. Morimoto et al. determined that patients on antiplatelet
therapy and anticoagulant therapy with INR <3.0 can safely undergo dental extractions
without risk of excessive bleeding [106]. Cocero et al. determined in patients with comorbid‐
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ities such as diabetes, liver disease, and kidney failure that the INR safety window should be
adjusted to <2.3 [107].
In patients undergoing surgical procedures with a higher risk of bleeding including head and
neck surgery and reconstructive plastic surgery, warfarin should be stopped 5 days preoper‐
atively [108]. The use of bridging anticoagulation with unfractionated heparin or low molec‐
ular weight heparin should be based on the thromboembolic risk of the patient. The American
College of Chest Physicians (ACCP) as part of the Perioperative Management of Antithrom‐
botic Therapy of the Antithrombotic Therapy and Prevention of Thrombosis 9th ed. has
developed a three‐tiered thromboembolic risk stratification of patients with mechanical heart
valves, atrial fibrillation, and history of venous thromboembolism [108]. The risk stratification
includes high risk (>10%/years of ATE or >10%/months of venous thromboembolic events
(VTE)), intermediate risk (4–10%/years risk of ATE or 4–10%/months risk of VTE), and low
risk (<4%/years risk of ATE or <2%/months risk of VTE). In patients at a high risk for throm‐
boembolism bridging anticoagulation is recommended [102]. In patients at low risk for
thromboembolism, bridging anticoagulation is not recommended [102]. In patients at moder‐
ate risk for thromboembolism, use of bridging anticoagulation should be determined on a case‐
by‐case basis [108]. In cases of excessive anticoagulation, the effects of warfarin can be stopped
by the administration of parenteral vitamin K, prothrombin complex concentrate (PCC), or
fresh‐frozen plasma; 4 factor PCC including factors II, VII, IX, and X are preferred over FFP
based on an increased rate of INR correction with fewer side effects [109].
3.2. Heparin and derivatives
3.2.1. Heparin (HMWH, unfractioned heparin
Heparin is an endogenously produced linear polysaccharide with anticoagulant effects [110].
Heparin binds to antithrombin, formerly known as antithrombin III, increasing the anticoa‐
gulant effect of antithrombin by a factor of 1000. The binding of heparin to antithrombin results
in a conformational change allowing for increased binding to clotting factors. Antithrombin
activation leads to the inactivation of thrombin, Factor IX, and Factor X [104]. HMWH is unique
compared to low molecular weight heparin and fondaparinux due to its ability to inhibit
thrombin. HMWH is able to inhibit thrombin by the formation of a complex between HMWH,
antithrombin, and thrombin that requires the long chains found in HMWH [111]. The molec‐
ular weight HMWH is 5000–30,000. In patients on HMWH, close monitoring via PTT is
necessary. The therapeutic levels of heparin are typically 1.5–2.5 normal PTT [112]. Typically,
the therapeutic range is 0.3–0.07 units/ml (anti‐Xa units), which is achieved via a bolus of 80–
100 units/kg, followed by 15–20 units/kg/h [113]. The onset of parenteral HMWH is nearly
immediate with a half‐life of 45 min to 1 h [114]. Low‐dose prophylaxis can be achieved with
5000 units subcutaneously every 8–12 h. Peak plasma concentration of subcutaneous heparin
occurs at 2–4 h post‐administration. In patients on bridging anticoagulation with heparin, it is
recommended that patients have HMWH discontinued 4–6 h prior to surgery with postoper‐
ative resumption of HMWH after hemostasis has been achieved [108]. In surgeries with a high
risk of bleeding, resumption of HMWH is done after 48–72 h [108]. The most common serious
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side effect of heparin treatment is heparin‐induced thrombocytopenia (HIT). HIT is a hyper‐
coagulable state that occurs in 1–4% of patients receiving unfractionated heparin due to
antibodies to platelet factor 4 and heparin [115]. The formation of a thrombus or sudden
decrease in platelet levels should raise suspicion for HIT. HMWH is metabolized by the liver
and is unaffected by renal function. Reversal of the anticoagulant effect of heparin is achieved
with the antagonist protamine. Protamine binds avidly to heparin reducing its anticoagulant
effect. For every 100 units of heparin remaining in the patient, 1 mg of protamine is adminis‐
tered. Protamine should be administered slowly at a maximum rate of 20 mg/min (not to
exceed 50 mg in a 10‐min period).
3.2.2. Low molecular weight heparin (enoxaparin, dalteparin, and tinzaparin)
Low molecular weight heparin (LMWH) is derived from HMWH to produce a polysaccharide
with a molecular weight of 2000–9000 Da [116]. LMWH, like heparin, leads to anticoagulation
by promoting antithrombin to inactive Factor X and II. LMWH has a greater effect on Factor
X compared to its effect on thrombin [98]. Advantages of LMWH over heparin include less
frequent dosing and more predictable anticoagulant response compared to HMWH, limiting
the need for laboratory monitoring. LMWH is unable to cross the placenta and is therefore the
ideal anticoagulant during pregnancy. Disadvantages of LMWH include delayed onset,
decreased effectiveness of protamine as a reversal agent, limitations in patients with renal
failure and inability to monitor by PTT [117]. For enoxaparin, full‐dose therapeutic levels
should be titrated to 0.5–1.0 units/ml antifactor Xa for twice‐daily dosing or 1.5 units/ml for
once‐daily dosing. Antifactor Xa should be used to measure activity of LMWH when indicated.
For enoxaparin, prophylaxis 30 mg twice daily or 40 mg once daily should be given subcuta‐
neously. Prophylactic dalteparin is typically administered as 5000 units every 8–12 h. Plasma
concentrations peak at 2 h for IV administered LMWH and after 3–5 h for subcutaneously
administered LMWH. The half‐life is approximately 2 h. In patients receiving therapeutic
subcutaneous LMWH as part of bridging anticoagulation, it is recommended that LMWH be
discontinued 24 h prior to surgery and continued 24 h post‐surgery pending hemostasis. In
higher bleeding risk surgeries, LMWH should be continued 48–72 h post‐surgery [108].
Protamine may be used to reverse the effects of LMWH. For LMWH administered in the last
8 h, 1 mg of protamine should be administered for every 1 mg of LMWH. For administration
of LMWH longer than 8 h, prior 0.5 mg of protamine should be administered for every 1 mg
of LMWH [118].
3.2.3. Fondaparinux (Arixtra)
Fondaparinux (Arixtra; GlaxoSmithKline, Mississauga, Ontario) is a small synthetic penta‐
saccharide fragment of heparin with a molecular weight of 1700 Da. Fondaparinux is an in‐
hibitor of Factor Xa with high affinity for antithrombin compared to HMWH [98].
Fondaparinux is approved for prophylaxis of venous thromboembolic events (VTE) for up
to one‐month post‐orthopedic surgery of the lower limbs, prophylaxis of VTE for patients
undergoing abdominal surgery with high risk of thromboembolic events and in the acute
treatment of DVT and pulmonary embolism [119]. Fondaparinux is not currently used for
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long‐term anticoagulation therapy. For prophylaxis, 2.5 mg of fondaparinux is administered
subcutaneously once daily beginning 6–12 h post‐surgery [120]. For VTE therapy, 5–10 mg is
administered subcutaneously once daily in a weight‐dependent manner. The half‐life of fon‐
daparinux is 17–21 h in patients with good renal function. The excretion of fondaparinux is
highly dependent on renal function as 77% of fondaparinux is excreted unchanged in the
urine within 72 h post‐administration in patients with good renal function under the age of
75 years [119]. In patients with moderate renal insufficiency, creatinine clearance 30–50 ml/
min, the half‐life of fondaparinux is 29 h, and in patients with severe renal insufficiency,
creatinine clearance <30 ml/min, the half‐life of fondaparinux is 72 h [119]. Due to its renal
excretion and concerns of prolonged bleeding, fondaparinux is contraindicated in patients
with severe renal insufficiency. Fondaparinux has advantages over traditional heparin in
terms of a reduced risk for heparin‐induced thrombocytopenia. Fondaparinux is not cur‐
rently approved for the use of “bridging,” and there are currently no randomized controlled
trials with fondaparinux used as a bridging therapy. There are limited case studies with fon‐
daparinux used as bridging therapy, with Wei et al. publishing a case report in a patient
with a history of HIT requiring perioperative bridging due to mitral valve replacement pri‐
or to resection of esophageal squamous cell carcinoma. The patient was successfully bridg‐
ed used 2.5 mg of fondaparinux subcutaneously, with the last dose of fondaparinux given
30 h preoperatively and resumed 24 h postoperatively [121]. In patients with HIT or antith‐
rombin deficiency, where heparins are contraindicated, the use of fondaparinux for perio‐
perative bridging may be indicated but further investigation is required. Initial
recommendations for discontinuation of fondaparinux preoperatively would be 3–5 half‐
lives, similar to other anticoagulants. This recommendation is based solely on expert opin‐
ion, with no differentiation between the 2.5 mg prophylaxis dose and 5–10 mg therapeutic
dose [122]. In patients with good renal function, this would be at least 2 days prior to a sur‐
gical procedure with minimal bleeding risk and 4 days prior to a surgical procedure with a
high risk of bleeding. In patients with mild‐to‐moderate renal dysfunction, these time points
should be adjusted accordingly [122].
3.3. Antiplatelet Therapy
3.3.1. Aspirin
Aspirin is used in the prophylactic treatment of myocardial infarction, stroke, and acutely in
acute coronary syndrome. For prophylaxis, patients regularly take 75–100 mg/day indefinitely
[123] with 81 mg being the most common dose in the United States. Aspirins mechanism of
action is the irreversible inhibition of cycloxygenase‐1 (COX‐1). By inhibition of COX‐1, there
is a decrease in formation in thromboxane A2 in platelets and therefore a decrease in platelet
aggregation [56]. As aspirin is an irreversible inhibitor of COX‐1, its effect is for the life span
of the platelet. For dentoalveolar surgery, rarely is discontinuation of aspirin recommended.
This is supported in the literature by Medeiros et al. who determined no difference in the
amount of bleeding that occurred during tooth extraction between patients who continued
prophylactic doses of aspirin therapy compared to those who suspended aspirin therapy [124].
In patients who are undergoing procedures with a high risk of bleeding including head and
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neck surgery and reconstructive plastic surgery, cessation of aspirin should be based on the
cardiovascular risk of the patient. In patients with a high risk for a cardiovascular event, aspirin
therapy should be continued perioperatively, and in patients with a low risk of a cardiovas‐
cular event, aspirin therapy should be discontinued 7–10 days prior to surgery [108]. Patients
at high risk for a cardiovascular event include those patients with congestive heart failure,
diabetes mellitus, renal insufficiency, ischemic heart disease, and cerebrovascular disease
[108].
3.3.2. P2Y12 receptor blockers
The P2Y12 blockers receptor blockers include clopidogrel, ticlopidine, prasugrel, ticagrelor,
and cangrelor. The P2Y12 blockers function by blocking the binding of ADP to the P2Y12
receptor on platelets, resulting in an inhibition of platelet aggregation [125]. Clopidogrel,
ticlopidine, and prasugrel are irreversible inhibitors of P2Y12 via prodrug conversion to active
metabolites, while ticagrelor and cangrelor are direct reversible inhibitors of P2Y12. As a result
of being irreversible inhibitors, there is a slower offset of action of clopidogrel, ticlopidine, and
prasugrel compared to the reversible inhibitors [126]. Clopidogrel is the prototypical P2Y12
receptor blocker, but it is not an ideal anticoagulant due to its slow onset of action due to being
a prodrug, unpredictable pharmacodynamics due to its p450 interactions, and slow offset as
an irreversible inhibitor. Ticlopidine use is limited due its side effect of severe neutropenia.
Prasugrel and ticagrelor have come into favor due to increased prevention of cardiovascular
events [127, 128]. Prasugrel and ticagrelor also carry a high risk of bleeding compared to
clopidogrel due to their faster onset and more consistent platelet inhibition [126]. P2Y12
blockers are commonly used along with aspirin for dual‐antiplatelet therapy in patients with
NSTEMI or coronary stent placement [129]. The current recommendation for patients with
drug eluding stents is at least 12 months of dual‐antiplatelet therapy, followed by an additional
18 months of dual‐antiplatelet therapy considering the increased risk for bleeding [130]. The
recommendations for bare metal stents are the same as for drug eluding stents with improved
outcomes at greater than 12‐month dual‐antiplatelet therapy [131]. In patients undergoing
dental extractions, Bajkin et al. determined that there was no increased risk in postoperative
bleeding in patients on dual‐antiplatelet therapy with clopidogrel and aspirin compared to
patients on no antiplatelet therapy [132].
3.4. Direct oral anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) including thrombin and Factor X inhibitors are being used
in treatment of stroke prevention in patients with atrial fibrillation, prophylaxis for venous
thromboembolism post‐surgery, in management of venous thromboembolism, in secondary
prevention of thromboembolism, and in heparin‐induced thrombocytopenia. DOACs are
contraindicated in patients with prosthetic heart valves, severe renal impairment, and during
pregnancy. Compared to warfarin, the DOACs have several advantages. This includes a rapid
onset of action, a relatively wide therapeutic range, and a decrease in need for regular
coagulation monitoring. Compared to heparin, DOACs have the advantage of oral bioavaila‐
bility. Direct factor inhibitors are also reported have an overall lower bleeding risk compared
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to warfarin [133]. With a decreased necessity for close monitoring, there is an increased concern
for patient compliance. While compliance between patients taking vitamin K antagonists and
DOACs may be equal, missing a single dose of a DOAC has an increased risk of anticoagulation
outside the therapeutic window compared to missing a single dose of warfarin [134]. Other
concerns include a current lack of specific antidotes. Direct thrombin inhibitors include
parenteral bivalirudin (Angiomax; The Medicines Company Parsippany, NJ, USA), argatro‐
ban, and desirudin. Bivalirudin is a synthetic analog to hirudin, a natural anticoagulant in the
saliva of leeches. Bivalirudin is renally excreted and in patients with adequate renal function
has a half‐life of 25 min. Similar to other DOACs, there is no antidote for bivalirudin. Bivalir‐
udin has been used as an alternative to heparin in patients with HIT [135, 136]. The only oral
direct thrombin inhibitor is dabigatran (Pradaxa; Boehringer Ingelheim Ridgefield, CT, USA).
There are no parenteral Factor X inhibitors. Oral Factor X inhibitors include rivaroxaban
(Xarelto; Janssen Pharmaceutica, Belgium), apixaban (Eliquis; Bristol‐Myers Squibb, New
York, NY, USA), and edoxaban (Lixiana; Daiichi‐Sankyo, Japan).
3.4.1. Dabigatran (Pradaxa)
Dabigatran is a competitive direct thrombin inhibitor. Thrombin is the final enzyme of the
coagulation cascade that cleaves fibrinogen into fibrin. In addition, thrombin also activates
factors V, VIII, XI, and XIII [137]. Dabigatran is able to block the action of both circulating and
clot bound thrombin therefore preventing the propagation of clots. This is unique from
heparin, which only blocks circulating thrombin [138]. Dabigatran is approved to reduce the
risk of stroke in atrial fibrillation, treatment of venous thromboembolism, and secondary
prevention of venous thromboembolism with a dosing of 150 mg twice a day in patients with
good renal function. In post‐surgical patients for prevention of venous thromboembolism,
110 mg is administered post‐surgery followed by 220 mg once daily for one to four weeks. The
prodrug dabigatran etexilate has a 6–7% oral bioavailability [139, 140]. Peak plasma concen‐
tration is achieved in 1–2 h and the half‐life ranges from 12 to 17 h [141]. The anticoagulant
effects of dabigatran last for 2–3 days. The drug is cleared renally and should be avoided in
patients with severe renal impairment [142]. Dabigatran has fewer drug interactions than
warfarin as it is not metabolized by the p450 system, but should be avoided in patients taking
amiodarone, verapamil, quinidine, and rifampin as these drugs increase the effects of dabi‐
gatran [139, 140]. The antidote for dabigatran is idarucizumab (Praxbind Boehringer Ingel‐
heim, Germany), a monoclonal antibody that can be used in emergency situations for reversal
of dabigatran [143]. In the RE‐LY trial, Eikelboom et al. determined that there was no increased
risk of bleeding with warfarin titrated to an INR of 2–3 compared to dabigatran 150 mg twice
a day [144]. There are currently no randomized controlled trials evaluating the risk of bleeding
in patients on dabigatran undergoing dental extractions. The limited evidence in managing
patients undergoing dental extractions indicates continuing anticoagulant treatment, delaying
extractions as long as possible since the last dosage of dabigatran, and the use of local hemo‐
static agents [145]. If dabigatran is to be interrupted preoperatively, renal function should be
considered. In patients with normal or mild impairment of renal function undergoing surgery
with low bleeding risk, the last dose should be administered 2 days before surgery, and in
patients with moderate renal impairment, the last dose should be administered 3 days before
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surgery. In patients with normal or mild impairment of renal function undergoing surgery
with a high bleeding risk, the last dose should be administered 3 days before surgery, and in
patients with moderate renal impairment, the last dose should be administered 4–5 days before
surgery [146]. In emergency situations, the safe concentration for dabigatran at which surgery
can be performed without the risk of major bleeding is less than 30 ng/ml. A PTT and PT ratio
of <1.2 compared to normal is indicative of a dabigatran concentration of <30 ng/ml. If PTT and
PT concentration is greater than 1.2 compared to normal, treatment should be delayed for 24 
h and new laboratory tests taken prior to treatment [147].
3.4.2. Rivaroxaban (Xarelto)
Rivaroxaban is a competitive direct Factor X inhibitor. Activated Factor X cleaves prothrombin
to thrombin. Rivaroxaban is able to bind to both circulating and clot bound Factor X, preventing
the propagation of clot formation. This is unique from heparin, which only binds to circulating
Factor X. Rivaroxaban is approved for prevention of stroke in patients with atrial fibrillation,
prevention of venous thromboembolism following surgery, and in the treatment and preven‐
tion of venous thromboembolism [108]. There is no prodrug for rivaroxaban. For post‐surgical
prophylaxis of VTE, 10 mg is used daily for 2–5 weeks; for treatment and prevention of VTE,
15 mg is given twice daily for 3 weeks followed by 20 mg once daily; for stroke prevention in
atrial fibrillation, 20 mg is used once daily in patients with good renal function. The oral
bioavailability is ∼80%. Peak plasma concentration is achieved in 2.5–4 h [108, 109]. Rivarox‐
aban has a half‐life of 5–9 h, and the anticoagulant effect lasts for 1–2 days [110]. One‐third is
excreted renally, and two‐thirds are converted by CYP 3A4 to inactive metabolites. Therefore,
strong p450 inhibitors and inducers may have significant drug interactions [148]. Rivaroxaban
is not recommended in patients with poor renal function or poor liver function [149]. There is
no known antidote for rivaroxaban. There are currently no randomized controlled trials
evaluating the risk of bleeding in patients on rivaroxaban undergoing dental extractions. As
part of the ROCKET AF Trial, Sherwood et al. determined that there was a higher risk of major
and minor GI bleeding compared to warfarin, but no difference in severe bleeding [150]. The
limited evidence in managing patients undergoing dental extractions indicates continuing
anticoagulant treatment, delaying extractions as long as possible since the last dosage of
rivaroxaban, and the use of local hemostatic agents. If rivaroxaban is to be interrupted
preoperatively, renal function should be considered. For patients with normal, mild, or
moderate impairment of renal function undergoing surgery with a low bleeding risk, the last
dose should be given 2 days prior to surgery, for a surgery with a high bleeding risk the last
dose should be given 3 days before surgery. For patients with severe impairment of renal
function, creatinine clearance less than 30 ml/min, undergoing surgery with a low bleeding
risk the last dose should be given 3 days before surgery and for a surgery with a high bleeding
risk the last dose should be given 4 days before surgery [106]. The concentration for rivarox‐
aban at which emergency surgery can be performed without major risk of bleeding is less than
30 ng/ml. Regular laboratory testing of rivaroxaban concentration is not always available, but
analysis of PT and PTT can act as a good indicator. A PTT and PT ratio of <1.2 compared to
normal is indicative of a rivaroxaban concentration of <30 ng/ml. If PTT and PT concentration
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is greater than 1.2 compared to normal, treatment should be delayed for 24 h and new
laboratory tests taken prior to treatment [107].
3.4.3. Apixaban (Eliquis)
Apixaban is a direct oral Factor X inhibitor. The half‐life of apixaban is 5–9 h [101]. Apixaban
can be used in post‐surgical VTE prophylaxis, treatment and prevention of VTE, and stroke
prevention patients with atrial fibrillation. Compared to other DOACs, apixaban has the least
risk for bleeding complications [151]. There are currently no randomized controlled trials
evaluating the risk of bleeding in patients on apixaban undergoing dental extractions. The
limited evidence in managing patients undergoing dental extractions indicates continuing
anticoagulant treatment, delaying extractions as long as possible (since the last dosage of
apixaban) and the use of local hemostatic agents. If apixaban is to be interrupted preopera‐
tively, renal function should be considered. In patients with normal or mild impairment of
renal function undergoing surgery with low bleeding risk, the last dose should be administered
2 days before surgery, and in patients with moderate renal impairment, the last dose should
be administered 3 days before surgery. In patients with normal or mild impairment of renal
function undergoing surgery with a high bleeding risk, the last dose should be administered
3 days before surgery, and in patients with moderate renal impairment, the last dose should
be administered 4 before surgery [106].
4. Local hemostatic agents
In many patients, local hemostatic agents are an efficient and cost‐effective way to limit blood
loss. By limiting blood loss in the perioperative period, there is a decreased need for additional
interventions and their associated morbidities, including blood transfusions and their associ‐
ated risks. The use of local hemostatic agents aids in preventing the need for the discontinua‐
tion of anticoagulant therapy that would place patients at risk of thromboembolic events.
Additionally, the use of local hemostatic agents is cost‐effective by decreasing the need for
follow‐up due to incidence of “rebleeding.” Local hemostatic agents can be divided into two
main categories: physical agents that provide scaffolding for clot formation and biologically
active agents that include clotting factors or antifibrinolytics that promote clot formation or
inhibit clot dissolution. Physical agents include bone wax, oxidized regenerated cellulose
(Surgicel; Ethicon, Neuchatel, Switzerland), and gelatin matrix (Gelfoam; Pfizer, New York,
NY, USA). Biologically active agents include topical thrombin (RECOTHROM; Zymogenetics,
Seattle, WA, USA), aminocaproic acid (AMICAR; Clover Pharmaceuticals, Marietta, GA,
USA), and tranexamic acid (IV Cyklokapron; Pfizer, New York, NY, USA) (oral tablet LYS‐
TEDA; Ferring Pharmaceuticals Saint‐Prex‐Switzerland).
Oxidized regenerated cellulose (Surgicel) is a resorbable sterile mesh that can be layered at a
bleeding surgical site. Surgicel has bactericidal properties due to its acidic pH [152]. This is an
advantage of Surgicel over other hemostatic agents, as the highly absorptive properties of other
physical hemostatic agents at a neutral pH have been shown to be a nidus for infection. The
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acidic pH of Surgicel may have a negative effect on other hemostatic agents, such as thrombin.
Surgicel is known to inhibit topical thrombin; thus, Surgicel and topical thrombin should not
be used together to promote hemostasis. Additionally, Alkan et al. and Loescher and Robinson
in two separate animal models have determined that Surgicel when placed in close proximity
to nerves may have a negative effect on peripheral nerve function [153, 154].
Gelfoam is a highly absorbable gelatin matrix prepared from purified porcine. Gelfoam is
highly pliable, can easily be placed in bleeding extraction sockets, and completely reabsorbs
in 4–6 weeks [155]. The main effect of Gelfoam is to act as a scaffold for coagulation. Gelfoam
has a neutral pH. The use of Gelfoam as a physical matrix combined with topical thrombin as
a biological agent is an effective way to obtain hemostasis. The highly absorptive property of
Gelfoam has been reported to act as a nidus for infection and granuloma formation.
HemCon Dental Dressing (Zimmer Holdings, HemCon Medical Technologies Inc., Beaverton,
OR, USA) is an absorbable chitosan derived dressing used for hemostasis in dental extraction
sites [156]. Advantages of HemCon include its antimicrobial properties and its ability to be
placed over extraction sockets compared to being placed in extraction sockets and sutured in
place [157]. CollaPlug (Zimmer Dental, Carlsbad, CA, USA) is an absorbable collagen based
agent that acts a physical matrix to promote the coagulation cascade in extraction sockets. The
absorbable collagen membrane is also marketed as CollaTape for closure of graft sites and
repair of Schneiderian membrane tears, as well as CollaCote to be placed over soft‐tissue donor
sites [158]. In a recent study, Pippi et al. compared HemCon to CollaPlug and found favorable
outcomes in patients on anticoagulant therapy undergoing dental extractions with INR less
than 3.5 with both hemostatic agents. The authors reported advantages of HemCon, such as
reduced operative time and improved soft‐tissue healing, which they attributed to obviating
the need for suturing [156].
Bone wax, a mixture of beeswax and isopropyl palmitate, is an inexpensive and effective way
of occluding small bleeding vessels in bone. Bone wax does not act as a scaffold for coagulation
or contain coagulation factors, but rather a compressive and occlusive dressing. Increased risk
of infection is reported with the use of bone wax [159].
Topical thrombin is able to convert fibrinogen to fibrin in the final step of the coagulation
cascade. Topical thrombin is available in a liquid form and can be an effective way to obtain
hemostasis when combined with Gelfoam or collagen matrices. As mentioned previously,
Surgicel and thrombin should not be used together.
Tranexamic acid and aminocaproic acid are antifibrinolytic agents composed of synthetic
lysine residues capable of blocking plasminogen and plasmin binding to fibrin. Tranexamic
acid can be administered intravenously or topically. In patients undergoing orthognathic
surgery, Choi et al. determined that a bolus of tranexamic acid (20 mg/kg) preoperatively
significantly reduced intraoperative bleeding compared to controls [160]. In a recently
published randomized control trial, Eftekharian et al. used tranexamic acid (1 mg/mL) in
combination with normal saline as an irrigant during orthognathic surgery and concluded that
there was a statistical significance in blood loss between the tranexamic acid irrigant and the
saline control irrigant, with the tranexamic acid irrigant reducing mean blood loss by >25%
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[161]. Gauze soaked in topical tranexamic acid is an effective way of gaining the hemostatic
effects of tranexamic acid post‐dental extraction patients. The use of a tranexamic acid
mouthwash as a hemostatic agent in post‐dental extraction patients is supported by Carter et
al. who found favorable outcomes of a 4.8% tranexamic mouthwash four times a day for 7 
days post‐dental extraction compared to a fibrin glue preparation in patients on anticoagulant
therapy [162, 163] (Table 2).
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